Evidence map›Paper›PMID 36295640›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Anti-CXCL8 Autoantibody: A Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma.

Huili Chen, Guiying Sun, Zhuo Han, Huimin Wang, Jiaxin Li, Hua Ye, Chunhua Song, Jianying Zhang, Peng Wang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Targeting p-FGFR1Biomedicines · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Huili ChenDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Guiying SunDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Zhuo HanDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Huimin WangState Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou 450052, China.
Jiaxin LiDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Hua YeDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0003-3657-2417
Chunhua SongDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.
Jianying ZhangState Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou University, Zhengzhou 450052, China.ORCID 0000-0003-2938-9526
Peng WangDepartment of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou 450001, China.ORCID 0000-0003-4666-9706
Zhengzhou University · CN

Funding

the Funded Project of International Training of High-level talents in Henan Province No NumberZhengzhou Major Project for Collaborative Innovation 18XTZX12007
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Squamous CellEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAutoantibodiesBiomarkers, TumorHumansPrognosisRNA, MessengerAutoantibodiesBiomarkers, TumorRNA, Messengeranti-cxcl8 autoantibodybioinformatic analysisbiomarkeresophageal squamous cell carcinoma

Identifiers

PMID36295640
PMCPMC9607113
OpenAlexW4306849704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.